IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia
Chen, Huan; Liu, Kai-yan; Xu, Lan-ping; Liu, Dai-hong; Chen, Yu-hong; Zhao, Xiang-yu; Han, Wei; Zhang, Xiao-hui; Wang, Yu; Zhang, Yuan-yuan; Qin, Ya-zhen; Liu, Yan-rong; Huang, Xiao-jun
关键词Philadelphia Chromosome Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Cell Transplantation Minimal Residual Disease Imatinib
刊名JOURNAL OF HEMATOLOGY & ONCOLOGY
2012-06-08
DOI10.1186/1756-8722-5-29
5
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Hematology
研究领域[WOS]Oncology ; Hematology
关键词[WOS]POLYMERASE-CHAIN-REACTION ; MARROW TRANSPLANTATION ; COMPLETE REMISSION ; CANCER PROGRAM ; CHEMOTHERAPY ; TRANSCRIPTS ; THERAPY ; RELAPSE ; REDUCTION ; INDUCTION
英文摘要

Background: Maintenance therapy with imatinib during the post-transplant period has been used for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL); however, its efficacy has not been demonstrated. A study was designed to investigate the safety of imatinib and its efficacy in preventing hematological relapse and improving disease-free survival (DFS) when administered after allogeneic hematopoietic stem cell transplantation (allo-HCT).

Methods: Patients with Ph + ALL that received allo-HCT were enrolled in the study. Real-time quantitative reverse-transcription polymerase chain reaction (qRT-PCR) was used to detect BCR-ABL transcript levels. Imatinib therapy was initiated if patient neutrophil counts were > 1.0 x 10(9)/L and platelet counts were > 50.0 x 10(9)/L, or if they displayed either elevated BCR-ABL transcript levels in two consecutive tests, or a BCR-ABL transcript level >= 10(-2) after initial engraftment. Patients receiving imatinib after relapse were assigned to the non-imatinib group. The imatinib treatment was scheduled for 3-12 months, until BCR-ABL transcript levels were negative at least for three consecutive tests or complete molecular remission was sustained for at least 3 months.

Results: A total of 82 patients were enrolled. Sixty-two patients initiated imatinib therapy post-HCT. Imatinib therapy was initiated at a median time of 70 days post-HCT. Grade 3-4 adverse events (AEs) occurred in 17.7% of patients. Ten patients (16.1%) terminated imatinib therapy owing to AEs. Among the patients in imatinib and non-imatinib groups, the estimated 5-year relapse rate was 10.2% and 33.1% (p = 0.016), and the 5-year probability of DFS was 81.5% and 33.5% (p = 0.000) with the median follow-up of 31 months (range, 2.5-76 months) and 24.5 months (range, 4-72 months), respectively. Multivariate analysis identified imatinib maintenance therapy post-HCT as an independent prognostic factor for DFS (p = 0.000, hazard ratio [HR] = 4.8) and OS (p = 0.000, HR = 6.2).

Conclusions: These results indicate that relapse rate can be reduced and DFS may be improved in Ph + ALL patients with imatinib maintenance therapy after HCT. BCR-ABLmonitoring by qRT-PCR can guide maintenance therapy with imatinib including initiation time and treatment duration after allo-HCT.

语种英语
WOS记录号WOS:000307009600001
项目编号30971292 ; 2011AA020105
资助机构National Natural Science Foundation of China ; National High-tech R&amp ; D Program of China ; Ministry of Health of China
引用统计
被引频次:33[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/53663
专题北京大学第二临床医学院_血液科
医学人文研究院/公共教学部_哲学与社会科学系
作者单位Peking Univ, Peoples Hosp, Inst Hematol, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Chen, Huan,Liu, Kai-yan,Xu, Lan-ping,et al. Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia[J]. JOURNAL OF HEMATOLOGY & ONCOLOGY,2012,5.
APA Chen, Huan.,Liu, Kai-yan.,Xu, Lan-ping.,Liu, Dai-hong.,Chen, Yu-hong.,...&Huang, Xiao-jun.(2012).Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia.JOURNAL OF HEMATOLOGY & ONCOLOGY,5.
MLA Chen, Huan,et al."Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia".JOURNAL OF HEMATOLOGY & ONCOLOGY 5(2012).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Chen, Huan]的文章
[Liu, Kai-yan]的文章
[Xu, Lan-ping]的文章
百度学术
百度学术中相似的文章
[Chen, Huan]的文章
[Liu, Kai-yan]的文章
[Xu, Lan-ping]的文章
必应学术
必应学术中相似的文章
[Chen, Huan]的文章
[Liu, Kai-yan]的文章
[Xu, Lan-ping]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。